Rapid test for the differentiated detection of influenza A and B with results in 15 minutes. BioStar OIA FLU A/B provides individual results for influenza A & B. The BioStar OIA FLU test provides a single result, with performance equivalent to 14-day viral culture. Easy to UseNo additional equipment required Multiple Specimen TypesNasal aspirate, nasopharyngeal (NP) swab, throat swab and sputum. Further Benefits of the BioStar OIA FLU A/B Test
DataPercent of Specimens Positive by the BioStar OIA FLU test or 14 Day Viral Culture
How to Choose Between
|
||||||||||||||||||||||||||||||
FLU |
FLU A/B |
|
Proven clinical performance |
|
|
STAT results |
|
|
Multiple specimen types |
|
|
OIA Technology |
|
|
Reliable product supply |
|
|
Allow for increased reimbursement |
|
|
Enable choice of antivirals for treatment of Flu A vs. Flu B |
|
|
Assist in surveillance of Flu A and Flu B |
|
|
Influenza is responsible for approximately 114,000 hospitali-zations and 36,000 deaths per year.1 Vaccination effectiveness varies among groups and is not 100% effective with any population.2
During the 2002-2003 flu season, influenza A viruses were reported more frequently than influenza B viruses (range 58% - 86%) in the New England, East North Central, Pacific, Mountain, and Mid-Atlantic regions, and influenza B viruses were reported more frequently than influenza A viruses (range 53% - 78%) in the West North Central, West South Central, South Atlantic, and East South Central regions.3
Bibliography & References
CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49 (No. RR-3)
Useful Downloads - US
Product Brochure
Package Insert
Procedure Card
CLSI Procedure
MSDS
International Downloads
Package Insert - INT